ALOX15 loss, common in CRC, impairs the cancer-preventative effects of fish oil, mouse study shows

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

About 19 million American adults consume dietary fish oil supplements. These supplements, which primarily consist of the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid, are widely used as a remedy for chronic diseases. However, the effects of EPA and DHA supplementation on cancer risk have been inconsistent.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.
Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login